AbbVie’s Parkinson’s Drug Wins English Funding After Economic Model Rethink
Executive Summary
AbbVie’s Produodopa, a new formulation of its Parkinson’s therapy Duodopa, is set to be made available to eligible National Health Service patients in England after the company made several significant changes to its original economic model.